News
MIST
2.150
-2.27%
-0.050
AptarGroup Announces That Its Bidose Liquid Nasal Spray System Liquid Is The Mechanism For Delivering The Newly Approved CARDAMYST
Benzinga · 14h ago
AptarGroup Wins FDA Approval for Bidose Nasal Delivery System in CARDAMYST Treatment
Reuters · 14h ago
Milestone Pharmaceuticals (MIST) Is Down 16.3% After First-in-Decades At-Home PSVT Drug Approval - Has The Bull Case Changed?
Simply Wall St · 21h ago
Milestone Pharmaceuticals Is Maintained at Overweight by Wells Fargo
Dow Jones · 1d ago
Milestone Pharmaceuticals Price Target Raised to $8.00/Share From $4.00 by Wells Fargo
Dow Jones · 1d ago
Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Raises Price Target to $8
Benzinga · 1d ago
MILESTONE PHARMACEUTICALS, INC. <MIST.O>: WELLS FARGO RAISES TARGET PRICE TO $8 FROM $4
Reuters · 2d ago
Milestone Pharmaceuticals price target raised to $8 from $4 at Wells Fargo
TipRanks · 2d ago
Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher
Seeking Alpha · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Brystol Myers, Nvidia
Reuters · 2d ago
Milestone Pharmaceuticals Raised to Buy From Hold by TD Cowen
Dow Jones · 2d ago
Milestone Pharmaceuticals Price Target Announced at $8.00/Share by TD Cowen
Dow Jones · 2d ago
TD Cowen Upgrades Milestone Pharmaceuticals to Buy, Announces $8 Price Target
Benzinga · 2d ago
Milestone Pharmaceuticals Price Target Raised to $8.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 2d ago
Milestone Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Raises Price Target to $8
Benzinga · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Vanda Pharma, Tesla, Zillow
Reuters · 2d ago
Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval
TipRanks · 2d ago
MILESTONE PHARMACEUTICALS INC <MIST.O>: TD COWEN RAISES TO BUY FROM HOLD
Reuters · 2d ago
Milestone Pharmaceuticals upgraded to Buy from Hold at TD Cowen
TipRanks · 2d ago
More
Webull provides a variety of real-time MIST stock news. You can receive the latest news about Milestone Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About MIST
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.